Anzeige
Mehr »
Sonntag, 07.12.2025 - Börsentäglich über 12.000 News
Breaking News: Das 1.000% Wachstum initiiert?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 882361 | ISIN: US5898891040 | Ticker-Symbol: MM3
Stuttgart
05.12.25 | 21:26
70,50 Euro
0,00 % 0,00
1-Jahres-Chart
MERIT MEDICAL SYSTEMS INC Chart 1 Jahr
5-Tage-Chart
MERIT MEDICAL SYSTEMS INC 5-Tage-Chart
RealtimeGeldBriefZeit
71,0072,0006.12.
71,0072,5005.12.

Aktuelle News zur MERIT MEDICAL SYSTEMS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.11.Executive Chairman Of Merit Medical Systems Sold $880K In Stock1
25.11.Insider Unloading: Fred Lampropoulos Sells $2.18M Worth Of Merit Medical Systems Shares1
21.11.Merit Medical Systems Executive Chairman Sold $424K In Company Stock1
14.11.Merit Medical to launch Wrapsody endoprosthesis in U.S. after CMS defers reimbursement decision4
14.11.Verzögerung bei Wrapsody: Canaccord senkt Kursziel für Merit Medical auf 93 US-Dollar2
MERIT MEDICAL SYSTEMS Aktie jetzt für 0€ handeln
14.11.Merit Medical stock price target lowered to $93 at Canaccord on Wrapsody reimbursement delay1
13.11.Merit Medical withdraws application for Medicare payment boost2
13.11.MERIT MEDICAL SYSTEMS INC - 8-K, Current Report-
05.11.Merit Medical Systems, Inc.: Merit Medical Releases 24-Month Efficacy Results from the Randomized Arteriovenous Fistula (AVF) Arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial144The target lesion primary patency (TLPP)1 and access circuit primary patency (ACPP)2 of the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) remain superior to percutaneous transluminal angioplasty...
► Artikel lesen
03.11.Merit Medical Systems, Inc.: Merit Medical Releases 24-Month Efficacy Results from the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY Arteriovenous Access Efficacy (WAVE) Trial148At 24 months, the target lesion primary patency (TLPP)1 was 41.7%At 24 months, the access circuit primary patency (ACPP)2 was 25.7% SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Merit Medical...
► Artikel lesen
31.10.Merit Medical Q3 Earnings & Revenues Beat Estimate, Margins Expand1
31.10.Where Merit Medical Systems Stands With Analysts3
31.10.Merit Medical targets $175M free cash flow in 2025 with updated guidance and new CEO at helm1
30.10.Merit Medical Q3 2025 slides: Revenue jumps 13%, guidance raised1
30.10.Merit Medical Systems Inc Q3 Profit Decreases, But Beats Estimates-
30.10.MERIT MEDICAL SYSTEMS INC - 10-Q, Quarterly Report1
30.10.MERIT MEDICAL SYSTEMS INC - 8-K, Current Report1
29.10.Exploring Merit Medical Systems' Earnings Expectations3
16.10.Merit Medical to acquire cryoballoon tech from Pentax3
16.10.Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition1
Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1